AML: State of the art - EN

Acute myeloid leukaemia (AML) is a heterogeneous disease for which much has changed in terms of diagnosis and classification in recent years. There are also new options with regard to treatment, especially for elderly patients and patients with many comorbidities or refractory/recurrent AML. This makes choosing the most appropriate therapy increasingly complicated. In addition, measurable residual disease (MRD) is playing an increasingly important role in choosing the right treatment and monitoring the disease.

In this Pharmacotherapy-Online publication, internist-haematologist Dave de Leeuw and resident internist-haematologist Remco Molenaar discuss the key developments in the diagnostic and treatment of AML. To this end, they consult the latest scientific publications and national/international AML guidelines. New treatment options are illustrated in the publication using interesting case histories.